162PMonitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCLC)
Di Noia, V, D’Argento, E, Vita, E, Ferrara, M, Damiano, P, Ribelli, M, Cannella, A, Virtuoso, A, Tortora, G, Bria, EVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz063.060
Date:
April, 2019
File:
PDF, 75 KB
2019
File converter
More search results
More benefits 
